Published: Jan 13, 2021 By Brandon May
Jonathan Weiss/Shutterstock
Major players in the biotech industry are moving full steam ahead in their 2021 operations goals despite the ongoing pandemic, with global pharmaceutical giant Takeda being no exception. The Japanese biopharmaceutical company
just announced it has entered into a broad strategic collaboration with KSQ Therapeutics to research, develop and commercialize novel immune-oncology agents using the latter company’s proprietary CRISPRomics® discovery platform.
The discovery platform will be used in clinical research to screen the entire human genome in an effort to find optimal gene targets for autoimmune and oncology disease. Under terms of the agreement, Takeda will obtain exclusive, worldwide and royalty-bearing license to develop, manufacturer and commercialize both cell and non-cell therapy candidates for the modulation of targets identified with KSQ’s CRISPRomics platform.
Atomwise et FutuRx lancent A2i Therapeutics : une nouvelle société d'immuno-oncologie financée par l'Autorité israélienne de l'innovation. – IsraelValley israelvalley.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from israelvalley.com Daily Mail and Mail on Sunday newspapers.
Press release content from Business Wire. The AP news staff was not involved in its creation.
Atomwise and FutuRx Launch A2i Therapeutics - A New Immuno-Oncology Company Funded By Leading Biopharma VCs and the Israeli Innovation Authority
December 18, 2020 GMT
SAN FRANCISCO & NESS ZIONA, Israel (BUSINESS WIRE) Dec 18, 2020
Atomwise, the leader in using artificial intelligence (AI) for small-molecule drug discovery, announced today a partnership with FutuRx, a recognized Israeli-based biotechnology incubator focused on innovative, early-stage therapeutic technologies. The collaboration will serve as the first introduction of Atomwise’s AtomNet® platform for AI-based drug discovery to a growing biotech innovation hub in Israel and is Atomwise’s second partnership with a global incubator hub.
(1)
A2i Therapeutics secures seed funding from FutuRx and its investors Johnson Johnson Innovation (JJDC, Inc.), Takeda Ventures, OrbiMed Partners, Leaps by Bayer and the Israeli Innovation Authority to develop novel small molecule immuno-oncology agents. Atomwise, the leader in using artificial intelligence (AI) for small-molecule drug discovery, announced today a partnership with FutuRx, a recognized Israeli-based biotechnology incubator focused on innovative, early-stage therapeutic technologies. The collaboration will serve as the first introduction of Atomwise s AtomNet platform for AI-based drug discovery to a growing biotech innovation hub in Israel and is Atomwise s second partnership with a global incubator hub.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201218005044/en/
Atomwise and FutuRx Launch A2i Therapeutics - A New Immuno-Oncology Company Funded By Leading Biopharma VCs and the Israeli Innovation Authority - Press Release digitaljournal.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from digitaljournal.com Daily Mail and Mail on Sunday newspapers.